Primary source: PUBLIÉ LE 20/03/2025 - MIS À JOUR LE 11/08/2026 Contraception et risque de méningiome : nouvelles recommandations Survei
Translated From French
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
The ANSM has initiated the distribution of personalized letters to women using desogestrel-based contraceptives starting from September 10, 2026, informing them about the associated risk of meningioma and advising on contraceptive management.
This communication highlights a significant safety signal, prompting necessary awareness and vigilance among patients and healthcare providers regarding potential health risks associated with long-term use of desogestrel.
Healthcare professionals should review the contraceptive needs of women annually and discuss the implications of continued desogestrel use, particularly in women over 45 or with a history of progestin use.
Regulatory Intelligence Lead
Annual
Healthcare professionals should review the contraceptive needs of women annually and discuss the implications of continued desogestrel use, particularly in women over 45 or with a history of progestin use.
The ANSM communicates the very low risk of meningioma linked to desogestrel (75 µg) contraceptives. An additional case of meningioma is observed for 67,000 women exposed. The letter encourages regular discussions about contraceptive suitability with healthcare providers, especially for women over 45 or with prior progestin exposure.
What changed: The ANSM has initiated the distribution of personalized letters to women using desogestrel-based contraceptives starting from September 10, 2026, informing them about the associated risk of meningioma and advising on contraceptive management.
Why it matters: This communication highlights a significant safety signal, prompting necessary awareness and vigilance among patients and healthcare providers regarding potential health risks associated with long-term use of desogestrel.
Practical implication: Healthcare professionals should review the contraceptive needs of women annually and discuss the implications of continued desogestrel use, particularly in women over 45 or with a history of progestin use.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitoring of the affected batches will be essential to ensure regulatory compliance and consumer safety, alongside implementation of any necessary recall procedures.
Review and update the labeling and training materials to include new user manual information for the Aspire Active Air 8 Pressure Care Mattress.
Healthcare providers should quarantine all impacted epidural kits and remove any sodium chloride ampules affected by this recall, implementing corrective actions per FDA guidance.
Review the updated guidance to incorporate the new compliance procedures starting from 1 January 2026, specifically regarding the electronic submission process.
